Evidence map›Paper›PMID 41219819›Full record

ArticleBreast cancer research : BCR2025

The role and prognostic value of mitochondria-related gene PARK7 in breast cancer.

Shuxian Yu, Yiming Zhou, Shuangyi Zhang, Fengwu He, Leting Jiang, Xiaoai Lv, Xidong Gu, Xiaohong Xie

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuxian YuDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Yiming ZhouDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Shuangyi ZhangDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Fengwu HeHangzhou Normal University, Hangzhou, China.
Leting JiangHangzhou Normal University, Hangzhou, China.
Xiaoai LvDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. lxa616@126.com.
Xidong GuDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. 20083011@zcmu.edu.cn.
Xiaohong XieDepartment of Breast Surgery, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China. xxh666857@163.com.

Funding

Zhejiang Provincial Science and Technology Project of Traditional Chinese Medicine 2026ZL0278
6 · The paper itself

Abstract

backgroundBreast cancer is the most common malignant tumor among women globally, with incidence and mortality rates ranking first among female cancers. Mitochondrial dysfunction plays a crucial role in the occurrence, development, and metastasis of breast cancer, but the specific mechanisms remain unclear. This study aims to explore the mechanisms and prognostic value of the mitochondrial-related gene PARK7 in breast cancer.

methodsThis study integrated summary data on the methylation levels, expression levels, and protein abundance of mitochondrial-related genes. The discovery phase data were sourced from the IEU GWAS database, while the validation phase data came from the FinnGen study dataset. Mendelian randomization and colocalization analyses were conducted to explore the potential associations between the methylation, expression, and protein abundance of mitochondrial-related genes and breast cancer risk. Clinical and pathological data, as well as gene expression data from breast cancer patients, were obtained from the TCGA database. Cox regression analysis was used to assess the relationship between PARK7 expression and clinical pathological features, and a prognostic model was constructed. Additionally, in vitro experiments were performed to verify the effects of PARK7 on triple-negative breast cancer cells.

resultsThe study found that high expression of the PARK7 gene is closely related to a reduced risk of breast cancer (OR 0.91, 95% Cl 0.88-0.95; PPH4 = 0.90), which was also validated in the FinnGen dataset. Patients with high PARK7 expression had longer survival times and higher survival probabilities in the TCGA database. In vitro experiments showed that overexpression of PARK7 significantly inhibited the proliferation, migration, and colony formation of triple-negative breast cancer cells, while promoting apoptosis and significantly increasing mitochondrial membrane potential, indicating altered mitochondrial function. Furthermore, Western blot analysis revealed that overexpression of PARK7 led to increased PTEN protein expression and decreased p-PI3K and p-AKT protein expression, suggesting that PARK7 may exert its tumor-suppressive effects by modulating the PI3K/Akt signaling pathway.

conclusionHigh expression of the PARK7 gene is closely related to reduced breast cancer risk and good prognosis, and it may exert its tumor-suppressive effects by regulating the expression of apoptosis-related proteins and migration-related proteins, as well as by affecting mitochondrial function and modulating the PI3K/Akt signaling pathway. It can serve as a potential biomarker for the diagnosis, treatment, and prognosis of breast cancer.

Indexed as

Biomarkers, TumorBreast NeoplasmsMitochondriaProtein Deglycase DJ-1Triple Negative Breast NeoplasmsCell Line, TumorCell MovementCell ProliferationDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPrognosisBiomarkers, TumorPARK7 protein, humanProtein Deglycase DJ-1Breast cancerIn vitro experimentsMendelian randomizationMitochondriaPARK7

Identifiers

PMID41219819
PMCPMC12606907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.